Congestive Heart Failure Tutorial

One of the costliest illnesses from both a financial point of view and a quality of life point of view is Congestive Heart Failure. Many organizations, including CMS, have initiated targeted CHF Treatment programs to address both. The reality is that a growing number of people are developing CHF at a younger age. And, aggressively treated, it is possible to decrease the morbidity, delay the mortality and decrease the cost of care for this illness.

This is why SETMA developed a CHF Clinic in which to aggressively treat patients with this illness through standardization of therapy and frequent monitoring of the patient's progress.

This disease management tool is built to the standards established by the Physician Consortium for Performance Improvement.

How to find the CHF Templates

AAA Home

Patient	Robert Home Phone Pa ti	Test Jr (409)888-888 atient's Code Sta	Sex M 38 Work Pho atus DNR ONE OF MO	Age 39 DOB 03/25/197 ne () -	<u>View Alerts</u>
<u>SETMA's LESS ir</u> <u>Ch</u> Master CR T N	i <u>tiative T P</u> arge Posting Tut	reventing Diabe orial ICD-9 C	<u>tes T Prevent</u> Code Tutorial <u>E8</u>	ing Hypertension T M M Coding Recommendations	edical Home Coordination Needs Attention!!
<u>Daily Progress</u> A	dmission Orders	<u>T</u> <u>Discharq</u>	<u>e T Insulin Infus</u>	sion Colorectal Surgery Pain M	anagement <u>T</u>
Exercise I	<u>CHF Exercise</u> Hydration <u>T</u>	<u>a T Diabetic I</u> <u>Nutrition T</u>	<u>Exercise T Dru</u> Guidelines <u>T</u> La	<u>g Interactions</u> <u>T</u> Smoking Cessa ab Future <u>T</u> Lab Results <u>T</u>	ion I
Acute Coronary Syn I Angina	<u>I Asthma</u> <u>Weig</u> t	Disea HF T Diabeta It Management	es Managemen es I Headaches I Renal Failure	t : <u>Hypertension</u> I Lipids I C Diabetes Edu	ardiometabolic Risk Syndrome T
Patient's Pharmacy	Pending Re	ferrals <u>T</u>			Chart Note
Daleo Pharmacy	Status	Priority	Referral	Referring Provider	Return Info
Phone (409)833-2255	-				Return Doc
Fax (409)833-8549					Email
Rx Sheet - Active					Telephone
Rx Sheet - New					Records Request
Rx Sheet - Complete				Þ	Transfer of Care Doc
Home Health	Anabian d.D.	-famala D		Referral History	
	Archived R	Drivetty	Beform!	Peterina Revider	
	Status	rhoney	Nerenai	Referring Provider	
•			1		

Master Tool Bar Icon

DOB 03/25/1970	-	D X
) -		
1		New Gutock
Select Template		······································
Medical Records Demographics		₽ 11/30/2009 10
		AAA Home
Sten 3		ICD9 - Whole
Step 5 tment		IMAssessmer
Dm Chf		E 🚊 \$ 11/23/2009 02
Dm Chf Exercise		AAA Home
Dm Chí Guide		
Dm Chf Otlab Dm Chf Plan		· · · · · · · · · · · · · · · · · · ·
		⊕ 🔤 \$ 11/16/2009 10
Step 2		⊕ \$ 10/20/2009 10
- Show		⊕
Categories 🗖		
Step 4		My Practice
OK Cancel		Step 1
December Demund		
Transfer of Care Doc		
Referral History		
ring Provider		👱 🖉 🌌
		F
•	┛	

SETMA's CHF Suite of Templates contains the following templates:

- 1. Master CHF
- 2. Nursing
- 3. Histories
- 4. Health
- 5. Questionnaires
- 6. System Review
- 7. Physical Exam
- 8. Radiology
- 9. Procedures

- 10. Treatment Guide
- 11. Treatment Plan
- 12. CHF Questionnaire
- 13. Flowsheet

U	HF Mana	gemer	ıt 👘	Patient Robe	rt Test Jr		Home
Goals of Therapy	Differentia	ting	Causes	Sex	M Age 39		Nursing
Diag	gnosing	Classificati	on				Histories
/ital Signs			Most Recent L	abs Check for Ne	w Labs		Health
Height	72.00 inches		Sodium	11	Cholesterol 150	06/06/2007	Questionnaires
Veight	.00 pound	5	Potassium	11	Triglycerides 175	06/06/2007	System Review
<u>əmi</u>			Chloride		HDL		Dhusical Evan
<u>Body Fat</u>	22 %		CO2				
<u>IMR</u>	cal/day	6	Glucose		Chol/HDL	-	Radiology
Vaist 	1.00 inches		BUN		Trig/HDL		Procedures
nips Risk Ratio	.00 inches		Creatinine Calcium		T3	11	Treatment Guide
Blood Pressure			Tropopip		T4	11	Treatment Plan
	/ mmHg		СРК	11	T7	11	CHE Questienneire
Pulse		_	Digoxin	11	T-Uptake	11	
ast Echo	11		PT	11	тѕн	11	Flowsheet
Ejection Fraction		Help	INR	11	proBNP	11	
/entricular Dys	Systolic	Help	Fibrinogen	11	Sed Rate		
HF Class	Class II	Help	PAI-1	11	D-Dimer	11	
ramingham 10-Y	r Risk	%					Patient Info
lortality Risk				Medical History	Labs Over Time		Provider Info
lobal Cardio Rist	1.4						CHF Primer
							Treatment
							Diagnosing Adults

Templates 2-9 are exact copies of the templates in the Master GP suite of templates. For explanations of these templates, please refer to the tutorial on the <u>Master GP</u>

The CHF tutorial will focus on:

- Master CHF template
- Treatment Guide template
- Treatment Plan template
- CHF Questionnaire template
- Flowsheet template

Master CHF Template

This template has a top portion and three columns below the materials which are presented at the top of the template.

Тор

- Title of the template
- Patient's name, gender and age
- Five buttons:
 - 1. Goals of Therapy
 - 2. Differentiating
 - 3. Causes
 - 4. Diagnosing
 - 5. Classification

CHF Management		Patient Robert	Test Jr		Home
Goals of Therapy Differentiating	Causes	Sex	M Age 39		Nursing
Diagnosing Classification	1				Histories
Vital Signs	Most Recent Labs	Check for New	Labs		Health
Height 72.00 inches	Sodium	11	Cholesterol 150	06/06/2007	Questionnaires
Weight .00 pounds	Potassium	11	Triglycerides 175	06/06/2007	System Review
BMI Podu Ect 22 W	Chloride	11	HDL I		Physical Exam
BMR cal/day	Glucose	11	Chol/HDL	1.11	Radiology
Waist .00 inches	BUN	11	Trig/HDL		Dracadurac
Hips .00 inches	Creatinine	11	UA Protein	11	Frocedures
Risk Ratio	Calcium	11	тз	11	Treatment Guide
Blood Pressure	Troponin	11	T4		Treatment Plan
Pulse	CPK		T-Untake		CHF Questionnaire
Last Echo //	PT	11	TSH	11	Flowsheet
Ejection Fraction Help		11	proBNP	11	
Ventricular Dys Systolic Help	Fibrinogen	11	Sed Rate	11	
CHF Class Class II Help	PAI-1	11	D-Dimer	11	
Hramingham 10-Yr Risk %	N	Andical History	Labs Over Time	r i	Patient Info
Global Cardio Risk 1.4		weatcarr instory	Labs Over Time	J	Provider Info
					Diagnosing Aduits

This pop-up gives the patient a sense of what the successful treatment of CHF should be. This material is printed on the CHF Follow-up note which is given to the patient. The pop-up states:

CHF M	lanagement P	Patient Robert Test Jr	Home
Goals of Therapy Dif	ferentiating Causes	Sex M Age 39	Nursing
Diagnosing	Classification		Histories
Vital Signs	Most Recent Labs	Check for New Labs	Health
Height 72.00	Service T	7 Obstantenet 150 06/06/007	Questionnaires
vVeight .0	Lhf Goals	× 107	System Review
BMI 21	Goals of	Therapy	Physical Exam
BMR		morapy	Radiology
Waist .0	* Improve Symptoms	Control	Radiology
Hips .0	* Improve Functional Capacity	* Systolic BP < 120 mmHg	Procedures
Risk Ratio	* Improve Quelity of Life	* Heart Rate	Treatment Guide
Blood Pressure	improve studinty of Ene		Treatment Plan
	* Slow or decrease progression	* VVeight	CHF Questionnaire
Pulse	* Decrease need for Hospitalization	* Fluid Volume	Flowsheet
Election Fraction	* Prolong Survival		
Ventricular Dys	Troong Surviva		
CHF Class	OK	Cancel	
Framingham 10-Yr Ri			Patient Info
Mortality Risk			Provider Info
Global Cardio Risk	1.4		CHF Primer
			Treatment
			Diagnosing Adults

Goals of Therapy

Clues for Differentiating between Systolic and Diastolic Dysfunction in patients with Heart Failure

One of the most important elements of the treatment of CHF is to determine whether the patient has Diastolic, Systolic or Combined Diastolic/Systolic failure, as the treatment of each differ significantly.

This pop-up lists 18 history, physical exam and procedure results from 5 categories, which are common in the evaluation and treatment of a patient with CHF. When the appropriate check boxes are marked and the "Calculate" button is depressed, a conclusion will appear which suggests the probability of the patient having systolic or diastolic CHF.

Note: It is a useful exercise to click one element at a time and then depressed "Calculate." This will allow you to see the probable impact each of the 18 elements have on the differentiation between systolic and diastolic dysfunction.

When you depress the button entitled **Differentiating**, the following directions and conclusion will be displayed:

"Select the following clues that are present in the evaluation of this patient. Click the 'Calculate' button at the bottom to view the conclusion."

Conclusion -- this will state "The presentation of symptoms is most suggestive of (Diastolic or Systolic) heart failure."

Image: Provide with the provided wi	olic
entricular D: HF Class Fourth Heart Sound (S3) Gallop Echocardiogram HF Class Fourth Heart Sound (S4) Gallop Decreased Ejection Fraction ramingham 1 Rales Dilated Left Ventricular ortality Risk Edema Dibal Cardio Displaced Point of Maximal Impulse Calculate Mitral Regurgitation Calculate	-

Causes of CHF

This is a good review of the differential diagnoses for the causes of CHF. Check Boxes are present to allow you to document any of the conditions which might affect this patient. Any elements of this pop-up which are captured elsewhere in the EMR are automatically populated here.

Diagnosing Heart Failure (Boston Criteria for Diagnosing Heart Failure)

This tool is based on the evaluation of three categories: History, Physical, and Chest Radiograph. Once the relevant elements are documented, depressing the "**Calculate**" button will display a result.

Each element has different values based on the weighted score developed by the Boston Criteria. For instance, "resting dyspnea," results in a score of 4, while "dyspnea climbing stairs," only rates a score of 1. The following is the scoring and the conclusions based on the numerical score:

1-3CHF Unlikely4-7CHF Possible8 and higher CHF Definite

The instructions on the pop-up state, "Select the following criteria for this patient and click "Calculate" to review the conclusion."

CHF Man	agement	Patient Robert	Test Jr	Home
Goals of Therapy Differen	iating Causes	Sex M	Age 39	Nursing
Diagnosing	Classification			Histories
Vital Signs Dm C	nf Diagdhf			×
Height72.00Weight.00BMI	Select the followin Category I - History Rest Dyspnea Orthopnea Paroxysmal Noc Dyspnea while v Dyspnea while v Category II - Physical Ex Heart Rate Abno Jugular Venous Hepatomega Edema Lung Crackles Basilar More than ba Wheezing Third Heart Sour	Diagnosing (Boston Criteria for D ng criteria for this patient turnal Dyspnea walking on level area climbing sam primality bipm Elevation cm H20 ly asilar nd	Heart Failure iagnosing Heart Failure) t and click calculate to re	view the conclusion.
4	Alveolar Pulmon Interstitial Pulmon Bilateral Pleural I Cardiothoracic r Upper zone flow	ary Edema nary Edema Effusion atio greater than 0.50 v redistribution	ОК	Cancel

Classification

This pop-up is instructional and addresses the various pathophysiological classifications of CHF. The pop-up allows you to check the box beside the type of CHF the patient has and this material will then print on the **CHF Follow-up note** and **CHF Chart Document**.

Classification of Heart Failure

Heart failure is defined as a pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to pump blood at a rate commensurate with metabolic requirements or to do so only from an elevated filling pressure.

CHF Managemen	t	Patient Robert	Test Jr		Home
Goals of Therapy Differentiating	Causes	Sex	M Age 39		Nursing
Diagnosing	on				Histories
Vital Signs	Most Recent Labs	Check for New	Labs		Health
Height 72.00 inches	Sodium	11	Cholesterol 150	¢6/06/2007	Questionnaires
rVeight00 pounds	Potassium	11	Triglycerides 175	06/06/2007	System Review
BM Rodu Ext 22 W	Chloride		HDL I		Physical Exam
BMR cal/day	Glucose		Chol/HDI		Radiology
Waist .00 inches	BUN	11	Trig/HDL		Dresedures
Hips .00 inches	Creatinine	11	UA Protein	11	Procedures
Risk Ratio	Calcium	11	тз	11	Treatment Guide
Blood Pressure	Troponin	11	T4		Treatment Plan
Pulse	СРК		T7		CHF Questionnaire
Last Echo //	Digoxin		тен		Flowsheet
Ejection Fraction Help	INR	11	proBNP	11	
Ventricular Dys Systolic Help	Fibrinogen	11	Sed Rate	11	
CHF Class Class I Help	PAI-1	11	D-Dimer	11	
Framingham 10-Yr Risk %				1	Patient Info
Mortality Risk	N	Medical History	Labs Over Time	J	Provider Info
Global Cardio Risk 1.4					CHF Primer
					Treatment
					Diagnosing Adults
•					

Definitions and descriptions are given for the following classes of CHF:

hf Class	
	Classification of Heart Failure
Heart failure is defined as a patho to pump blood at a rate commensu	ohysiological state in which an abnormality of cardiac function is responsible for failure of the heart rate with metabolic requirements or to do so only from an elevated filling pressure.
npe C	haracteristics
Diastolic Dysfunction	Normal myocardial contractility, left ventricular volume, and ejection fraction; impaired myocardial relaxation; diminished early diastolic filling. The heart is stiff and does not relax normally after contracting. Even though it may be able to pump a normal amount of blood out of the ventricles, the stiff heart does not allow as much blood to enter its chambers from the veins. As in systolic dysfunction, the blood returning to the heart then
	accumulates in the veins.
Systolic Dysfunction	Absolute or relative impairment of myocardial contractility, low ejection fraction. In systolic dysfunction, the heart contracts less forcefully and cannot pump out as much of the blood that is returned to it as it normally does. As a result, more blood remains in the lower chambers of the heart (ventricles). Blood then accumulates in the veins.
🔲 High Output Heart Failure	Bounding pulses, wide pulse pressure, accentuated heart sounds, peripheral vasodilatation, increase cardiac output and ejection fraction, moderate four-chamber enlargement.
Low Cardiac Output Syndrome	Fatigue, loss of lean body mass, prerenal azotemia, peripheral vasoconstriction, reduced left or right contractility.
☐ Right Heart Failure	Dependent edema, jugular venous distention, right atrial and ventricular dilatation, reduced right-sided contractility. This occurs when the left ventricle functions poorly. Water may build up within the lungs causing shortness of breath or coughing. The shortness of breath can occur during physical exertion (eg, climbing a flight of stairs), while straining (eg, lifting a heavy object), or can happen when lying down. An individual may be awakened from sleep by this shortness of breath and start coughing. Feeling tired or weak can also occur.
Left Heart Failure	Dyspnea, pulmonary vascular congestion, reduced left-sided contractility. This occurs when the right ventricle functions poorly. The volume of blood returning to the heart is decreased, causing swelling (edema) of the body. This fluid build-up is usually first noted in the ankles but can progress up the legs and into other parts of the body. Weight gain can also occur because of the extra water retained within the body.
E Biventricular Heart Failure	Dyspnea, dependent edema, jugular venous distention, pulmonary vascular congestion, bilateral reduced contractility. CHF is usually a combination of both RIGHT-SIDED and LEFT-SIDED Heart Failure.

Beneath these five buttons are three columns on the Master CHF Template

Column 1

Vital Signs

Height
Weight
BMI
Body Fat
BMR
Waist
Hips
Risk Ratio
Blood Pressure
Pulse
Last Echo -- this will interact with the Heath Maintenance template to note the date of the last echo.
Ejection Fraction -- the percent value for the ejection fraction should be manually entered here.
Ventricular Dysfunction -- the evaluation of whether the patient has diastolic or systolic

dysfunction, both or neither, needs to be documented here. When this is documented here, it interacts with the Treatment Guide template.

CHF Class -- the description of the classes of CHF are attached to this name. When this is documented here, it interacts with the Treatment Guide template.

Framingham 10-Yr Risk -- this documents the Framingham Risk Score. For information on how to use the Framingham template see the Framingham tutorial.

Mortality Risk -- this is a new algorithm which assesses the risk of short term death from CHF. This was developed for in-patient use and has limited benefit in the outpatient setting.

Global Cardio Risk -- for information on this score and its significance see the Framingham tutorial.

CHF Managemen	t	Patient Robert	Test Jr		Home	^
Goals of Therapy Differentiating	Causes	Sex	M Age 39		Nursing	
Diagnosing Classificatio	n				Histories	
Vital Signs	Most Recent Labs	Check for New	Labs		Health	
Height 72.00 inches	Sodium	11	Cholesterol 150	06/06/2007	Questionnaires	
v/eight _00 pounds	Potassium	11	Triglycerides 175	06/06/2007	System Review	
BMI Body Fet 22 %	Chloride				Physical Exam	
BMR cal/day	Glucose	11	Chol/HDL	1 · · ·	Radiology	
vVaist inches	BUN	11	Trig/HDL		Procedures	
Hips .00 inches	Creatinine	11	UA Protein		Treatment Guide	
Risk Ratio Blood Pressure			T4	11	Treatment Plan	
/ mmHg	СРК	11	17	11	CHE Questionnaire	
Pulse	Digoxin	11	T-Uptake	11	Elowebeet	
Election Fraction Help	PT	11	TSH		Flowsheet	
Ventricular Dys Systolic Help	Fibrinogen	11	Sed Rate	11		
CHF Class Class II Help	PAI-1	11	D-Dimer	11		
Framingham 10-Yr Risk%				1	Patient Info	
Mortality Risk		Medical History	Labs Over Time	J	Provider Info	
Giobal Cardio Nisk					CHF Primer	
	•				Diagnosing Adults	
					Diagnooling Addito	
						•

Column 2

Check for New Labs

Most Recent Labs

Medical History -- this launches a pop-up on which 14 different issues related to cardiac history are documented. Where this information is captured in the EMR, it is auto posted here. Where it is not, it will need to be manually added.

Labs Over time

CHF Managemer	nt	Patient Rober	t Test Jr		Home
Goals of Therapy Differentiating	Causes	Sex	M Age 39		Nursing
Diagnosing Classificat	ion				Histories
Vital Signs	Most Recent Labs	Check for New	/Labs		Health
Height 72.00 inches	Sodium	11	Cholesterol 150	06/06/2007	Questionnaires
Veight pounds	Potassium	11	Triglycerides 175	06/06/2007	System Review
	Chloride		HDL		Physical Exam
BODY Fat 22 %	CO2				Destalent
Alaist .00 inches	BUN		Tria/HDI	-	Radiology
Hips .00 inches	Creatinine	11	UA Protein	11	Procedures
Risk Ratio	Calcium	11	тз	11	Treatment Guide
Blood Pressure	Troponin	11	T4	11	Treatment Plan
/ mmHg	СРК	11	77	11	CHF Questionnaire
Pulse	Digoxin	11	T-Uptake	11	Flawshast
Last Echo 77	PT		TSH		Flowsneet
Ejection Fraction J Help			proBNP		
CHE Class Class II Help	PAI-1	11	Sed Rate		
Framingham 10-Yr Risk			D-Dimer J		Patient Info
Mortality Risk		Medical History	Labs Over Time		Provider Info
Global Cardio Risk 1.4			J —	1	CHE Primer
	100 C				Treatment
					Diagnosing Adults
					F

X

Dm Chf Medhx **Medical History** ● No C Yes History of myocardial infarction? ⊙ No ○ Yes Hypertension No C Yes Valvular Heart Disease ⊙ No ○ Yes Diabetes ● No ○ Yes Peripheral Vascular Disease No C Yes Hypercholestrolemia No C Yes Rheumatic Fever ● No ○ Yes Chest Irradiation ● No C Yes Exposure to Antineoplastic Agents (e.g. Anthracycline, Trastuzunab) O No 💿 Yes - Alcohol Use 🖲 No 🔘 Yes 🛛 Illicit Drug Use ○ No ④ Yes Does the patient smoke? ● No ● Yes Exposure to Sexually Transmitted Disease ● No ○ Yes Family History of Atherosclerotic disease or cardiomyopathy, sudden death, conduction system disease and cardiomyopathy OK Cancel

Column 3

Navigation Buttons

	Home
herapy Differentiating Causes Sex M Age 39	Nursing
Diagnosing Classification	Histories
ns Most Recent Labs Check for New Labs	Health
72.00 inches Sodium // Cholesterol 150 06/06/2007	Questionnaires
.00 pounds Potassium // Triglycerides 175 06/06/2007	System Review
Chloride // HDL //	Diversional Duran
22 % CO2 // LDL //	Physical Exam
cal/day Glucose /// Chol/HDL	Radiology
.00 inches BUN /// Trig/HDL	Procedures
00 inches Creatinine /// UA Protein ///	in a star a star O s di da
2 00 Calcium 177 T3 177	reatment Guide
ssure Troponin // T4 /// 74	Treatment Plan
/ mmHg СРК Т7 // СН	IF Questionnaire
Digoxin // T-Uptake //	Elevenhant
PT 11 TSH 11	Flowsneet
raction Help INR // proBNP ///	
ar Dys Systolic Help Fibrinogen // Sed Rate //	
s Class II Help PAI-1 J // D-Dimer J //	
am 10-Yr Risk %	Patient Info
Risk Labs Over Time	Provider Info
rdio Risk 1.4	CHF Primer
	Treatment
Di	iagnosing Adults

The final five buttons within the navigation scheme are all document related.

Patient Info – This button will launch a pop-up window that will allow the user to choose from a list of 15 patient-related documents.

C	CHF Manageme	nt Patient Robert 1	est Jr Home
Goals of Therap	by Differentiating	Causes Sex M A	ge 39 Nursing
Di	iagnosing Classific	ation	Histories
Vital Signs	Dm Chf	Docs	Health
Height	72.00 inches		06/06/2007 Questionnaire
Weight	.00 pounds	Patient Information	06/06/2007 System Review
BMI	er	-	Physical Exam
BMR	caliday	C Welcome Letter	Rediclogy
Waist	.00 inches	What is CHF?	Radiology
Hips	.00 inches	How is CHF Treated? Treatment Options	Procedures
Risk Ratio	.00	C Recovery Prospects	Treatment Guid
Blood Pressure	<u> </u>	C Low Sodium	1 / Treatment Pla
J	/ mmHg	What is Echocardiogram?	CHF Questionna
Fuise Last Echo		C When To Call Your Doctor	Flowsheet
Ejection Fractio		C CPET	
Ventricular Dys	s Systolic	C Fluid Restriction	11
CHF Class	Class II	C CHF and Inactivity	11
Framingham 10	I-Yr Risk		Patient Info
Mortality Risk			Provider Into
Global Cardio R	(<u>lsk</u> 1.4		CHF Primer
		OK	Treatment
			Diagnosing Adu

Provider Info – This button will launch a pop-up window that will allow the user to choose from a list of 20 provider-related documents.

CHF Management Patient Robert Test Jr	Home
Goals of Therapy Differentiating Causes Sex M Age 39	Nursing
Diagnosing Classification	Histories
Vital Signs	Health
Height 72.00 inches 06/06/2007	Questionnaires
Weight 0.00 pounds Provider Information	7 System Review
Body Fat 22 % CHF Introduction //	Physical Exam
BMR Cal/day Causes of CHF Couses of CHF	Radiology
Waist .00 inches C Drug Therapy for CHF Hins 00 inches C Aggressive Treatment is Necessary 1.1	Procedures
Risk Ratio .00 Pathophysiology of CHF // Risk Ratio .00 C BP. Heart Pate District Heart Failure / /	Treatment Guide
Blood Pressure O Types of CHF	Treatment Plan
Pulse C-Reactive Protein 77	CHF Questionnaire
Last Echo // C Glitazones and Insulin //	Flowsheet
Ejection Fraction O DHF II / /	
CHF Class Class II C Forms of Heart Failure / /	-
Framingham 10-Yr Risk C Left, Right-Sided Heart Failure	Patient Info
Mortality Risk C Characteristics of DHF	Provider Info
Global Cardio Risk 1.4 Causes of DHF	CHF Primer
OK	Treatment
	Diagnosing Adults
•	

CHF Primer -- This button will launch a pop-up window that will allow the user to choose from a list of 14 documents designed to educate in the area of CHF.

CH	HF Manag	ement	Patient Robert	Test Jr]	Home	_
Goals of Therapy	Differentiating	g Causes	Sex M	Age 39]	Nursing	
Diag	gnosing C	lassification				Histories	
Vital Signs		Most Recent Labs	Check for New Labs			Health	
Height	72.00 inches	Dm Chf Primedocs		x	6/06/2007	Questionnaires	
vVeight	.00 pounds				6/06/2007	System Review	
Body Est	22 %	In	formation			Physical Exam	
BMR	cal/day	C Pathophy	ysiology			Radiology	
vVaist	.00 inches	O Patient H	listory Exemination			Procedures	
Hips	00 inches	C Causes of	of CHF		11	Treatment Guide	
<u>Risk Ratio</u> Blood Pressure	1.00	C Different	tial Diagnosis pry Studies		11	Treatment Plan	
· · · · · · · · · · · · · · · · · · ·	/ mmHg	C Imaging S	Studies		11	CHE Questionnaire	
Pulse		C Procedur	res - Catheterization		11	Chill Questionnaire	
Last Echo		C Staging o	of CHF Care			Flowsheet	
Ventricular Dys	Systolic		Heart Failure Treatment		11		
CHF Class	Class I	E O Newer T O Surgical	herapies for Heart Failure Care	•	11		
Framingham 10-Y	<u>ir Risk</u> %					Patient Info	
Mortality Risk		OK	Cancel			Provider Info	
<u>Global Cardio Risk</u>	<u> </u>					CHF Primer	
					-	Treatment	
						Diagnosing Adults	
							_
•							

Treatment – This button will launch a single document for printing entitled "**Outpatient Treatment of Systolic Heart Failure**".

Diagnosing Adults – This button will launch a single document for printing entitled **"Diagnosis of Heart Failure in Adults**".

		and a second	505.575 E			
CF	HF Manager	nent	Patient Rober	t Test Jr		Home
Goals of Therapy	Differentiating	Causes	Sex	M Age 39		Nursing
Diag	nosing Class	sification				Histories
Vital Signs		Most Recent La	bs Check for Nev	v Labs		Health
Height	72.00 inches	Sodium	11	Cholesterol 150	06/06/2007	Questionnaires
Weight	.00 pounds	Potassium	11	Triglycerides 175	06/06/2007	System Review
<u>BMI</u>		Chloride		HDL		Physical Exam
Body Fat	22 %	CO2				Destatem
IA/aist	.00 inches	BUN			-	Radiology
Hips	.00 inches	Creatinine	- 11	UA Protein	11	Procedures
Risk Ratio	.00	Calcium	11	тз	11	Treatment Guide
Blood Pressure		Troponin	11	T4	11	Treatment Plan
/	mmHg	СРК	11	77	11	CHE Questionnaire
Pulse		Digoxin	11	T-Uptake	11	
Last Echo		PT	11	тѕн	11	Flowsheet
Ejection Fraction	Hel	P INR	_ //	proBNP		
Ventricular Dys	Systolic Hel	p Fibrinogen		Sed Rate		
CHF Class	Piele Or	p PAI-1 J		D-Dimer	11	
Martality Riak	<u>r Risk</u> 70		Madical History	Labe Over Time		Patient Info
Olehel Centie Diel	14		iviedical history			Provider Info
Global Cardio Risk						CHF Primer
						Treatment
						Diagnosing Adults

Treatment Guide Template

This template guides you through the 12 steps of the standard treatment of CHF. They are:

- 1. Atrial Fibrillation or History of Thromboembolism?
- 2. Diastolic Dysfunction
- 3. Systolic Dysfunction Symptoms of Volume Overload
- 4. Add ACEI & Titrate to Target Dose?
- 5. Ace intolerant
- 6. NYHA Class I HF? (Help)
- 7. NYHA Class II HF? (Help)
- 8. Acceptable Level of functional Status
- 9. Add Digoxin (IF no Bradycardia)
- 10. Acceptable level of functional Status
- 11. Recent NYHA Class IV HF and Class III Or Class IV Symptoms (Help)
- 12. Acceptable Level of Functional Status

Also at the bottom of the template is a Cardiologist Referral Template.

Step by Step Review of Treatment Guide Template

The first five steps have the following instruction permanently displayed on the template, "Continue to Next Question." After that, this instruction appears according to your response. (See below)

Step 1 – Atrial Fibrillation or History of Thromboembolism?

There are two choices:

- No, if the patient does not have atrial fibrillation
- Yes, if the patient does have atrial fibrillation

No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	CHF Guidelines	Return
• No	Diastolic Dysfunction? Continue to Next Question	C Yes	
• No	Systolic Dysfunction Symptoms of Volume Overload?	O Yes	
	Continue to Next Question		_
No	Add ACEI & Titrate to Target Dose? Continue to Next Question	O Yes	
• No	Ace Intolerant?	C Yes	
1	Continue to Next Question		•

If the answer is, "No," move on to Step 2.

If the answer is "Yes," the following will appear in two columns:

		CHF	Guidelines	Cournadin
O No	Atrial Fibrilation or History of	• Yes	Anticoagulate with Warfarin	
	Continue to Next Question		Patient Refuses Cournadin	Cournadin Refer

Column 1 –

- Anticoagulate with warfarin
- **Patient refuses Coumadin** this is a check box which allows you to document the patient's refusal to begin Coumadin.

Note: If the patient refuses Coumadin, it is important to document the reason why. When you check the box beside the "Patient Refuses Coumadin," a pick list appears with the following options:

		CHF	Guidelines	Cournadio
© No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	• Yes	Anticoagulate with Warfarin Patient Refuses Cournadin	Medrefusal
⊙ No	Diastolic Dysfunction? Continue to Next Question	O Yes		allergy economical medical religious
⊙ No	Systolic Dysfunction Symptoms of Volume Overload?	O Yes		Close

Column 2 –

There are two buttons which are entitled:

- **Coumadin** this takes you to the **Coumadin Template** which will be discussed elsewhere.
- Coumadin Refer this launches the referral template with which you may send the patient to Coumadin clinic. When you depress this button, you will be asked whether to associate a template or not. Click "This template" and then click OK. An e-mail will appear which can be send to referral. The patient will then be called with an appointment to the Coumadin Clinic.

.95		CHF	Guidelines	Cournadin
No Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	Yes	Anticoagulate with Warfarin		
	Continue to Next Question		Patient Refuses Cournadin	

To the right of Step 1 is a Return button which will take you back to the Master CHF template,

		CHE	Cuidelinee		
C No.	Atvial Eilevilation of Llistows of		Guidemies	Cournadin	
Thromboembolism?	105	Anticoagulate with Warfarin	Cournadio Refer	Deturn	
	Continue to Next Question	xt Question	Patient Refuses Cournadin	Countralin restor	Return

Step 2 -- Diastolic Dysfunction

There are two choices:

- No, if the patient **does not** have Diastolic Dysfunction
- Yes, if the patient **does** have Diastolic Dysfunction

Note: If the echocardiogram data is filled out at the bottom of Column I on the Master CHF Template and if the ventricular dysfunction – either diastolic or systolic – is completed, Step 2 will have been automatically completed before you go to the Treatment Guide.

• No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	CHF C Yes	Guidelines	Return
⊙ No	Diastolic Dysfunction? Continue to Next Question	C Yes		
No	Systolic Dysfunction Symptoms of Volume Overload?	O Yes		
	Continue to Next Question			
No	Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes		
• No	Ace Intolerant?	C Yes		
1	Continue to Next Question			×

If the answer is, "No," move on to Step 3.



If the answer is, "Yes," the following three instructions will appear:

- 1. Adequate blood pressure control
- 2. Diuretic
- 3. Control Ventricular rate with CCB's



In the third, column there are the following three drugs and/or classes of drugs which can be used in Diastolyic Dysfunction:

- Digoxin
- Nitrates
- Beta-Blockers and ARBs

C No	Diastolic Dysfunction? Continue to Next Question	• Yes	Adeqaute blood pressure control Diuretic Control ventricular rate with CCB's	Help Help Help	Digoxin Nitrates Beta-blockers, ARBs	Brand Name
------	---	-------	--	----------------------	---	------------

In a second column are three **Help** buttons which have the following content:

O No Diastolic Dysfunction? Continue to Next Question Yes	Digoxin Nitrates Beta-blockers, ARBs
---	---

© №	Diastolic Dysfunction? Continue to Next Question	• Yes	Adequite blood pressure control Diuretic Control ventricular rate with CCB's	Help Digoxin Help Beta-block ARBs	Brand Name
-----	---	-------	--	---	------------

© №	Diastolic Dysfunction? Continue to Next Question	Yes	Adequite blood pressure control Diuretic Control ventricular rate with CCB's				
Nitrate	5		X				
1	Vasodilators which lower blood pre-	sure are a	associates with tachycardia that inhibits diastolic filling and aggravate diastolic CHF.				
			(CK)				
Digo	ĸin			<			
4	Digoxin is not recommended with the exception of a patient with atrial fibrillation. On the other hand, it car improve symptoms and decrease hospitalizations in paitents with isolated diastolic dysfunction. (Digitalis Investigation Group Trial)						
			OK				

There is then a link to the Medication Module. For instructions on how to use the Medication Module, <u>Click Here</u>. At each point in the CHF treatment guide that medications are recommended, you will find a link to the Medication Module.

Step 3 – Systolic Dysfunction Symptoms of Volume Overload

There are two choices:

- No, if the patient does not have Systolic Dysfunction
- Yes, if the patient does have Systolic Dysfunction

Note: If the echocardiogram data is filled out at the bottom of Column I on the Master CHF Template and if the ventricular dysfunction – either diastolic or systolic – is completed, Step 3 will be automatically completed.

		CHF	Guidelines	_
• No	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	O Yes		Return
• No	Diastolic Dysfunction? Continue to Next Question	C Yes		
⊙ No	Systolic Dysfunction Symptoms of Volume Overload?	O Yes		
	Continue to Next Question			
⊙ No	Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes		
⊙ No	Ace Intolerant?	C Yes		
	Continue to Next Question			

If the answer is, "No," proceed to Step 4. If the answer is, "Yes," the following will appear.

			Add Diuretic; Titrate Eu	volumic State		Brand Name
O No	Systolic Dysfunction Symptoms of Volume Overload?	• Yes	Bumetanide Hydrochlorthiazide Indapamide Metozolone	Bumex HCTZ Lozol Zaroxolyn	0.5 - 10 mg/day 12.5 - 50 mg/day 2.5 - 5 mg/day 5 - 20 mg/day	
	Continue to Next Question		Patient Refuses Diu	retic		

Beside this list is a link to the Medication Module

Beneath this list is a box entitled **Patient Refuses Diuretic**. The pick list associated with the box is:

C No	Systolic Dysfunction Symptoms of Volume Overload?	Yes	Add Diuretic; Titrate Euvolumic State	0.5 - 10 mg/day 12.5 - 50 mg/day 2.5 - 5 mg/day 5 - 20 mg/day	Brand Name
	Continue to Next Question		Pitient Refuses Diuretic	Medrefusal	×
• No	Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes		economical medical religious social	
(No	Ace Intelerent?	C Ves			Close

Step 4 – Add ACEI & Titrate to Target Dose?

There are two choices:

	CHF	Guidelines		
Atrial Fibrilation or History of Thromboembolism? Continue to Next Question	O Yes		Return	
Diastolic Dysfunction? Continue to Next Question	C Yes	,		
Systolic Dysfunction Symptoms of Volume Overload?	C Yes			
Continue to Next Question				
Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes			
Ace Intolerant?	C Yes			
Continue to Next Question				•
	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question Diastolic Dysfunction? Continue to Next Question Systolic Dysfunction Symptoms of Volume Overload? Continue to Next Question Add ACEI & Titrate to Target Dose? Continue to Next Question Ace Intolerant? Continue to Next Question	Atrial Fibrilation or History of Thromboembolism? Continue to Next Question Yes Diastolic Dysfunction? Continue to Next Question Yes Systolic Dysfunction Symptoms of Volume Overload? Yes Add ACEI & Titrate to Target Dose? Continue to Next Question Yes Ace Intolerant? Yes Continue to Next Question Yes	Atrial Fibrilation or History of Thromboenholism? C Yes Diastolic Dysfunction? C Yes Continue to Next Question C Yes Systolic Dysfunction Symptoms of Volume Overload? C Yes Add ACEI & Titrate to Target Dose? C Yes Continue to Next Question C Yes Add ACEI & Titrate to Target Dose? C Yes Continue to Next Question C Yes Ace Intolerant? C Yes	Atrial Fibrilation or History of Thromboembolsm? O Yes Return Diastolic Dystunction? O Yes Return Diastolic Dystunction? O Yes Yes Systolic Dystunction Symptoms of Volume Overload? O Yes Yes Continue to Next Question O Yes Yes Add ACEI & Titrate to Target Dose? O Yes Yes Continue to Next Question O Yes Yes Ace Intolerant? O Yes Yes Continue to Next Question Yes Image: Continue to Next Question Ace Intolerant? O Yes Image: Continue to Next Question

If you choose, "Yes," the following will appear:

Link to Medication Module



Patient Refuses an ACE

If the patient refuses an ACE, a pick list for the reasons pops up from which you should select the applicable one.

O No	Add ACEI & Titrate to Target Dose? Continue to Next Question	• Yes	Catopril Capoten Enalapril Vasotec Fosinopril Monopril Lisinopril Prinivil, Zestril Altace Ramipril	6.25 - 50 mg TID 2.5 - 20 mg BID 5 - 40 mg QD 1.25 - 10 mg QD 1.25 - 10 mg QD Medrefusal	
⊙ No	Ace Intolerant?	O Yes		allergy economical medical religious social	
	Continue to Next Question			Close	

Step 5 – ACEI tolerant?

There are two options:

Answer, "No," if the patient is not intolerant of ACEIs.

Answer, "Yes," if patient had to stop ACEIs due to cough, etc. If you answer that the patient is intolerant of ACEIs, the following appears:

	Continue to Next Question		Return	*
© No	Diastolic Dysfunction? Continue to Next Question	O Yes		
No	Systolic Dysfunction Symptoms of Volume Overload?	C Yes		
	Continue to Next Question			
• No	Add ACEI & Titrate to Target Dose? Continue to Next Question	C Yes	-	
⊙ No	Ace Intolerant?	C Yes		
	Continue to Next Question			
● No	NIVHA Class I HE? Heln		 •	-

Medication Module link

			Consider HydralazineA	sosorbide Dinit	rate or ARB	Brand Name
C No	o Ace Intolerant?	Yes	Hydralazine Isosorbide Dinitrate Eprosartan Candesartan Irbesartan Losartan	Teventen Atacand Avapro Cozaar	75 - 300 mg QD - QID 30 - 160 mg QD - TID 400 - 800 mg QD - BID 4 - 32 mg QD - BID 75 - 300 mg QD 25 - 100 mg QD	
	Continue to Next Question		☐ Olmesartan ☐ Telmisartan ☐ Valsartan	Benicar Micardis Diovan	5 - 40 mg QD 20 - 80 mg QD 80 - 320 mg QD	
			Patient refuses an A	ARB		

Patient refuses an ARB

O No	Ace Intolerant? Continue to Next Question	● Yes	Consider Hydralazine/Isoson Hydralazine Isosorbide Dinitrate Eprosartan Ata Irbesartan Ava Losartan Coz Olmesartan Ben Telmisartan Mica Valsartan Diov	bide Dinitrate c 2 enten 4 cand 4 pro 7 aar 2 icar 5 ardis 2 van 8	75 - 300 mg QD - QID 30 - 160 mg QD - TID 00 - 800 mg QD - BID - 32 mg QD - BID 5 - 300 mg QD 5 - 100 mg QD - 40 mg QD 0 - 80 mg QD 10 - 320 mg QD Medrefusal	Brand Name	
• No	NYHA Class I HF? <u>Help</u>	C Yes			allergy economical medical religious social		
No	NYHA Class II - III HF? <u>Help</u>	C Yes				Close	

Step 6 – NYHA Class I HF?

Note: If the Class of CHF is filled out at the bottom of Column I on the Master CHF Template, Step 6 will be automatically completed.

⊙ No	NYHA Class I HF? <u>Help</u>	C Yes	
• No	NYHA Class II - III HF? <u>Help</u>	C Yes	
• No	Acceptable level of functional status? Continue to Next Question	C Yes	
• No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes	
• No	Acceptable level of functional status? Continue to Next Question	C Yes	
	Recent NYHA Class IV HF and Help Class III or Class IV symptoms?	C Yes	▼ ▼

If the patient does not have NYHA Class I HF, proceed to Step Seven.

If the answer is, "Yes," i.e., the patient has NYHA Class I HF, the following will appear



Step 7 – NYHA Class II – III HF?

● No	NYHA Class II - III HF? Help Continue to Next Question	C Yes	
• No	Acceptable level of functional status? Continue to Next Question	C Yes	
• No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes	
⊙ No	Acceptable level of functional status? Continue to Next Question	C Yes	
• No	Recent NYHA Class IV HF and Help Class III or Class IV symptoms?	C Yes	
• No	Continue to Next Question Acceptable level of functional status?	C Yes	
			↓▼

Note: If the Class of CHF is filled out at the bottom of Column I on the Master CHF Template, Step 6 will be automatically completed.

There are two options:

If, the answer is "No," you move on to Step 8. If the answer is "Yes," the following pops up:

Medication Module Link



Patient Refuses a B-Blocker – document the reason why the patient refused.

-			Add a B-blocker; Titrate to target dose	Brand Name
O No	NYHA Class II - III HF? Help	Yes	Metoprolol Metoprolol XL Bisoprolol Zebeta Carvedilol Coreg	12.5 - 200 mg QD 1.25 - 10 mg QD 3.125 - 25 mg BID
	Continue to Next Question		Patient refuses a B-blocker	Medrefusal
• No	Acceptable level of functional status? Continue to Next Question	O Yes		allergy economical medical religious social
⊙ No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes		Close

Help—there are help buttons on Step 6, 7 and 10 which give the descriptions of the Four Classes of Congestive Heart Failure. If the Class is checked on the pop-up, it will interact with all other places where the Class of CHF is captured.

• No	Acceptable level of functional Continue to Next Questio	status? O Yes				
• No	Add Digoxin (If No Bradycardia Continue to Next Questio	a) CYes				
• No	Acceptable level of functional Continue to Next Questio	status? O Yes				
No No	Recent NYHA Class IV HF and Class III or Class IV symptoms Continue to Next Questio	<mark>r Help</mark> O Yes				
• No	Acceptable level of functional	status? O Yes				
	Refer to Cardiologis	st				Back To Top
	Status F	Priority	Referring First	Referring Last	Referral	
-						

Step 8 – Acceptable Level of Functional Status?

If the answer is "Yes," the following appears:



If the answer is, "No," then the following instruction appears, "Continue to Next Question."

Step 9 – Add Digoxin (if no Bradycardia)

	Continue to next sucstion					
No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes				
• No	Acceptable level of functional stat	us? O Yes				
• No	Recent NYHA Class IV HF and H Class III or Class IV symptoms?	elp O Yes				
• No	Acceptable level of functional stat	us? O Yes				
	Refer to Cardiologist					Back To Top
	Status Priorit	у	Referring First	Referring Last	Referral	
	1					1
						•

If the answer is "Yes," the following appears:

Trough level 6 hrs post dose should be monitored for:

- 1. HF worsens or renal function deteriorates
- 2. Signs of toxicity develop (like nausea, vomiting, confusion, visual disturb)
- 3. Dose adjustments are made
- 4. Meds added (e.g. antibiotics, amiodarone, quinidine, vararpamil, anticholinergics)

Medication Module link

O No	Add Digoxin (If No Bradycardia) Continue to Next Question	• Yes	 Trough level 6 hrs post dose should be monitored for: 1. HF worsens or renal function deteriorates 2. Signs of toxicity develop (like nausea, vomiting, confusion, visual disturb, etc) 3. Dose adjustments are made. 4. Meds added (e.g. antibiotics, amiodarone, quinidine, varapamil, anticholinergics) 	Brand Name
------	--	-------	--	------------

If the answer is "No," the following appears, "Continue to Next Question."

Step 10 – Acceptable level of functional Status?

	Continue to next vacati	on				
• No	Add Digoxin (If No Bradycard Continue to Next Questi	ilia) O Yes on				
No	Acceptable level of functions Continue to Next Questi	alstatus? O Yes				
• No	Recent NYHA Class IV HF ar Class III or Class IV symptom	nd Help O Yes s?				
	Continue to Next Questi	on				
© No	Acceptable level of functions	al status? 🖸 Yes				
	Refer to Cardiologi	st				Back To Top
	Status	Priority	Referring First	Referring Last	Referral	
		10 STOTE # 20				
	I					
						•

If the answer is "yes," the following appears:

3. Manage concomitant cardiac conditions	C No	Acceptable level of functional status?	• Yes	STOP	1. Continue present management 2. Schedule regular follow-up 3. Manage concomitant cardiac conditions	
--	------	--	-------	------	---	--

If the answer is "no," the following appears, "Continue to Next Question."

		011					
● No	Add Digoxin (If No Bradycard Continue to Next Questio	lia) O Yes					
• №	Acceptable level of functiona	al status? O Yes					
• No	Recent NYHA Class IV HF an Class III or Class IV symptom	nd Help O Yes s?					
	Continue to Next Question	on					
⊙ No	Acceptable level of functiona	al status? 🔘 Yes					
	Refer to Cardiologi	st				2	Back To Top
	Status	Priority	Referring First	Referring Last	Referral		
	•					•	
•							•

Step 11 – Recent NYHA Class IV HF and Class III or Class IV symptoms?

Help – see above

If the answer is, Yes," the following appears

Medical Module Link

O No	Recent NYHA Class IV HF and Help Class III or Class IV symptoms?	• Yes	Consider Spironolactone Brand Name Spironolactone Aldactone 25 - 100 mg QD Patient refuses spironolactone
	Continue to Next Question	4	

Patient refuses – document the reason for refusal

O No	Recent NYHA Class IV HF and Help Class III or Class IV symptoms?	∫⊙ Yes	Consider Spironola Spironolactone Patient refuses s	ctone Aldactone pironolactone	25 - 100	mg QD I I I I I I I I I I I I I I I I I I	
	Continue to Next Question		_			allergy	
No	Acceptable level of functional status?	C Yes				economical medical religious social	
-	Refer to Cardiologist						То Тор
	Status Priority		Referring First	Referring Last	Referral		

Step 12 – Acceptable Level of functional capacity?

	Continue to next sucation					
• No	Add Digoxin (If No Bradycardia) Continue to Next Question	C Yes				^
No	Acceptable level of functional status	? O Yes				
• No	Recent NYHA Class IV HF and Hell Class III or Class IV symptoms?	O Yes				
	Continue to Next Question					
⊙ No	Acceptable level of functional status	? O Yes				
	Refer to Cardiologist					Back To Top
	Status Priority		Referring First	Referring Last	Referral	i
					Þ	
41						· · · · · · · · · · · · · · · · · · ·

If the answer is "yes," the following appears:





1. Continue present management 2. Schedule regular follow-up 3. Manage concomitant cardiac conditions

If no, the following instruction appears, "Refer to Cardiologist."

	Continue to next edestion					
• No	Add Digoxin (If No Bradycardia) Continue to Next Question	O Yes				
⊙ No	Acceptable level of functional status? Continue to Next Question	C Yes				
● No	Recent NYHA Class IV HF and Class III or Class IV symptoms?	C Yes				
	Continue to Next Question					
• No	Acceptable level of functional status?	C Yes				
	Refer to Cardiologist	ð				Back To Top
	Status Priority		Referring First	Referring Last	Referral	
	I					
•						▼ ►

CHF Treatment Plan Template

Across the top of this template are links to:

- Lipids
- Diabetes
- Metabolic Syndrome
- Weight Management
- Hypertension

Each of these conditions contributes to the development and/or worsening of CHF. The effective treatment of CHF includes the effective management of each of these five areas.



Down the left hand side of this template there are the following buttons and/or links:

- Hydration
- Seven Steps to Success
- Focus of Treatment
- Evaluation
- General Measures
- Fluid Management
- Weight Loss
- Exercise
- Smoking Cessation
- Lung Congestion
- CHF compliance
- Meds Precipitating CHF
- Additional Management
- Follow up Instructions

• CHF Compliance E-Mail

	CHF 1	Freatment Pla	เท		_
Hydration	Lipids Diabetes	Metabolic Syndrome W	eight Management Hyp	pertension	
Seven Steps to Success					Return
Focus of Treatment	CHF Status	s 🔿 Improved 🔿 N	lo Change 🛛 C. Wors	e -	Document
Evaluation	Ordering Provid	er er en 		-	Follow Up Doc
General Measures	Laboratory		Immunizations		
Fluid Management		🗖 Potassium	Flu Shot	Pneumovax	
Weight Loss Info	proBNP				
Exercise		Thyroid Profil	e Dv 1		
Smoking Cessation			Dx 2		
Lung Congestion	Lipid Panel w	ADL Chinaryolo	re Dx3		
CHF Compliance	Radiology				
Meds Precipitating CHF Info	🗖 EKG	🗌 Chest PA/Lat			
Additional Management		Chest 1 View			
Follow Up Instructions					
CHF Compliance Email		Medication	Info		
Referrals (double-click to add)		Medications (double-o	lick to add)	Follow Up	Information
Priority Referring First Referring	Last Referral	Brand Name	Dose 🔺		Echocardiography Relense Costrol
		HYDROXYZINE HCL	25MG		Take Care Self
		apidra	100 unit p	Education Booklet Give	en Lifestyle Changes
	F		Tuo unit p	11	
Priority Referring First Referring	Last Referral	Brand Name HYDROXYZINE HCL apidra apidra ◀	Dose	Education Booklet Give	Echocardiography Relapse Control Take Care Self Lifestyle Changes

Four of these are explained in tutorials linked below:

- <u>Hydration</u>
- Weight Loss
- Exercise
- Smoking Cessation

The other eleven are functions which are:

- 1. Educational for the provider
- 2. Educational for the patient
- 3. Evaluational as to how the patient's care for CHF is proceeding

Each of the eleven **CHF-Template-Plan-Template Pop-ups**, which are specific to the CHF templates, will be explained below.

• **Hydration** – because dehydration and azoemia are such common problems in patients with CHF, this link to the **Hydration Evaluation Template** allows for you to document the state of the patient's hydration while treating their volume overload due to CHF.

Hyd	Iration Assessment	
Setting	Clinic ONursing Home CHospital OHospital Discharge	
Increased Risk of Dehydration Recent Infection Febrile Temp Recent Weight Loss Impaction Decreased Appetite Change in Mental Status Paralysis Inability to Feed Self Diabetes Mellitus On Diuretics Hypoalbuminemia Age over 60 Nursing Home Resident Nausea Nausea w/vomitting Diarrhea Unable to turn and position	Hospital O Hospital Discharge Physical Evidence of Dehydration Skin Turgor Buccal Mucosa Urine Output < 30 cc/hr Orthostatics Pulse //	Return Print Help Documents Degree of Dehydration Electrolytes and Osmolarity Ethical Issues about Hydration Factors Affecting Creat, BUN Fluid Requirements Osmolality Norms Osmolality Theory Renal Physiology and Hydration Signs of Dehydration
Metabolic & Chemical Analysis of Urine Specific Gravity Glucose Sodium Potassium Chloride HCO ₃ Hydration Status Calculate	Hydration Calculate BUN Serum Osmolality Creatinine Serum Osmolarity BUN/Creat Ratio Info Check for New Labs Info Laboratory Dates Est. Creat Clearance C Good Marginal C Adequate Dehydrated	
•		

• Seven Steps to CHF Treatment Success – this document allows you to review seven steps which are crucial to the success of treating CHF. These seven steps are imperative to effective treatment of CHF.

Dm Chf Sevensteps

Seven Steps to CHF Tr	reatment Success
 Control Risk Factors hypertension eliminating alcohol use diabetes eliminating tobacco use CAD ACE Inhibitor or Angiotensin Receptor Blocker All patients with heart failure should be taking an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-receptor blocker. In the absence of contraindications, an ACE inhibitor is preferred. In most patients, physicians should consider adding a beta blocker to ACE-inhibitor therapy. Spironolactone In patients with severe heart failure, spironolactone is a useful addition to baseline drug therapy, as is carvedilol (Coreg) (substitute carvedilol if patient is already taking a beta blocker). Aerobic Exercise Patients with stable heart failure should be encouraged to begin and maintain a regular aerobic exercise program. 	 Digoxin Digoxin therapy may reduce the likelihood of hospitalization but does not reduce mortality. It must be monitored closely, with a target dosage level of 0.5 to 1.1 ng per mL. Diuretic and Sodium Intake Symptoms may be controlled with the use of diuretics and restricted dietary sodium. Patient Education Patient education, with the patient's active participation in the care, is a key strategy in the management of heart failure. Periodic follow-up between scheduled office visits, which is essential in the long-term management of heart failure. telephone calls from the office nurse maintenance of daily symptoms weight diary participation in a disease management program

• Focus of CHF Treatment – this pop-up documents the four sites of action of CHF treatment: preload reduction, afterload reduction, inhibition of RAAS system and Inotropic support.

×



• Evaluation

This is an interesting tool for evaluating the patient with CHF. By following a series of questions with yes and no answers, you are led through a differential diagnosis of the patient with possible CHF.

This pop-up is entitled, "Evaluation of Heart Failure."

The process begins with the following instruction, "Begin answering the questions to the left. Additional questions and/or recommendations will appear."

E∨aluati	ion of Heart Failure	-
Begin answering the questions to the left	. Additional questions and/or recommendations will appear.	
Dyspnea present? O Yes O No	Return	
Medical History anemia hypertension cardiotoxic medications infectious disease chest irradiation peripheral vascular disease collagen vascular disease pheochromocytoma CAD rheumatic fever diabetes mellitus STDs hemochromatosis thyroid disease hypercholesterolemia valvular heart disease	Physical Exam pallor tachycardia pericardial rub cardia carrhythmia pericardial rub cardia carrhythmia pulmonary rales dependent edema third heart sound displaced cardiac apex weight loss or gain elevated blood pressure abnormal deep tendon reflexes heart murmur diminished peripheral pulses or arterial bruits joint inflammation hepatomegaly or hepatojugular reflux jugular venous distention thyromegaly or thyroid nodule	
alcohol finternational travel drugs	Laboratory Tests ANA Liver Function Test BMP Metanephrines	
CAD Skeletal myopathy cardiac conduction abnormality sudden death	CMP I Rheumatoid Factor (if connective tissue disease suspondent of the second connective tissue disease suspected connective tissue disease supeconnecting connective tissue disease suspected connective tissue	ectei
		•

The first question is, **"Dyspnea Present?"** if the answer is, "no," the recommendation is **"consider other causes."** If the answer is "yes," the recommendation is **Obtain ECG and chest radiograph."**

Begin ans	Evaluati swering the questions to the left	on of Heart Failure . Additional questions and/or recommendations	will appear.
Dyspnea present?	🔍 Yes 🔍 No	Obtain ECG and chest radiograph.	Return
ECG or chest radiograph ab	normal? O Normal O Abnormal		

This second question asks, **"ECG or chest radiograph abnormal?,"** if the answer is normal, the recommendation is, **"consider other causes."** If the answer is **"abnormal**," the recommendation is, **"obtain echocardiogram."**

Begin answering	Evaluation the questions to the left. Add	of Heart Failure litional questions and/or recommendations will app	ear.
Dyspnea present?	⊙Yes CNo	Obtain ECG and chest radiograph.	Return
ECG or chest radiograph abnormal?	C Normal	Obtain echocardiogram.	
Echocardiogram results?	O Normal O Abnormal O Technically Unsatisfactory		

The third question is **,"echocardiogram results?"** If the response is, "normal," the recommendation is **"consider other causes."** If the response is "abnormal," the recommendation is **"more detailed history, physical and laboratory testing. See below."**

Dyspnea present?	• Yes • No	Obtain ECG and chest radiograph.	Return
ECG or chest radiograph abnormal?	C Normal 💿 Abnormal	Obtain echocardiogram.	
Echocardiogram results?	O Normal O Abnormal	More detailed history, physical, and laboratory testing. See below.	

A second option under the third question is related to the echocardiogram and states, "Technically unsatisfactory." If the echo is considered "technically inadequate," the recommendation is "obtain radionucleotide scan."

The fifth question is **"Radionucleotide scan results."** If the answer is normal, the recommendation is, **"consider other causes."** If the answer is "abnormal," the recommendation is **"more detailed history, physical, and laboratory testing. See below."**

Begin answering	Evaluation the questions to the left. Add	of Heart Failure itional questions and/or recommendations will app	ear.
Dyspnea present?	• Yes C No	Obtain ECG and chest radiograph.	Return
ECG or chest radiograph abnormal?	C Normal 💿 Abnormal	Obtain echocardiogram.	
Echocardiogram results?	Normal C Abnormal Technically Unsatisfactory	Obtain radionucleotide scan.	
Radionucleotide scan results?	O Normal O Abnormal		

Beneath this series of questions is a section which includes:

Dyspnea present?	Yes U No	Obtain ECG and chest	radiograph.
ECG or chest radiograph abnormal?	C Normal 💿 Abnormal	Obtain echocardiogram	n.
Echocardiogram results?	C Normal C Abnormal Technically Unsatisfactor	Obtain radionucleotide	scan.
Radionucleotide scan results?	C Normal C Abnormal		
Medical History hyp cardiotoxic medications infe chest irradiation peri collagen vascular disease phe CAD rheu diabetes mellitus STD hemochromatosis thyr Nypercholesterolemia valv Social History inter drugs inter Family History cardiomyopathy CAD skel cardiomyopathy cardiomyopathy	ertension ctious disease pheral vascular disease ochromocytoma umatic fever bs roid disease vilar heart disease rnational travel letal myopathy diac conduction abnormality	Physical Exam acnycardia bronze skin cardiac arrhythmia displaced cardiac apex elevated blood pressure heart murmur joint inflammation jugular venous distention taboratory Tests ANA BMP CMP Electrolyte Panel HIV (in high risk patients) Lipid Panel CBC	 pallor pericardial rub pulmonary rales third heart sound weight loss or gain abnormal deep tendon reflexes diminished peripheral pulses or arterial bruits hepatomegaly or hepatojugular reflux thyromegaly or thyroid nodule Liver Function Test Metanephrines Rheumatoid Factor (if connective tissue disease suspected Serum Ferritin TSH Urinalysis Viral Titers (if patient had recent viral infection)
•			• • • • • • • • • • • • • • • • • • •

Each of these categories gives the opportunity to review and think about pertinent issues related to CHF, its diagnosis and evaluation. Some of the information will have already auto-populated from other parts of the EMR

The laboratory tests listed on this pop-up, when checked, will appear either on the CHF Plan template, or on the Laboratory Charge Posting template, if the lab test is not listed on the Plan template.

Note: If you check in the review of this **Evaluation** template that a lab test needs to be ordered and if that lab test is not on the CHF Plan template, it will be necessary to:

- Go to the Master GP Lab Charge Posting template
- Uncheck the lab test(s) which were placed there from the CHF Evaluation template
- Select the ICD-9 Codes
- Re-select the lab tests which you indicated you want to order from the CHF Evaluation template
- Click Submit to charge posting.



Acute Diagonses	Clear Diagnosis Field	LADOFATORY UPDERS s Ordering Provider Holly James	Submit E-mail Common Neurology	Orders
	Acetominophen ACTH Albumin Albumin Aldosterone, Serum Alkaline Phosphate Iso Allergy, Adult Food Allergy, Childhood ALT Aut	Diagnosis Code Mstr Description AA Branched Chain Dis Maple Syrup Urine AA Disorders Specified AA Disorders Unspecified AA Eley Homocusteine	Icd9cm Code Id User Description 2703 RxHCC 2708 RxHCC 2709 RxHCC 2704 RxHCC	×
hronic Diagnoses Abd Pain Rebound Tenc Hyperten Benign Esser Cardiac, Coronary Occl AA Metabolism Disorder Abn Acid/Base Disorde	Ambuatorie Ambuatorie Ambuatorie Ambuatorie Anylase Anylase Anylase Apo A1 Apo B Apo E (Alzheimers) AST B12 Beta 2 Microglobulin Bilirubin, Direct BMP BMP, Fasting BNP BUN C3	AA Fanconi Syncrome AA Histidine Metabolism Disturbance AA Metabolism Disorder AA Phenylketonuria AA Straight-chain Glucoglycinuria AA Urea Cycle Metabolism Distubance Abd Pain Epigastric Abd Pain Generalized Abd Pain LLQ Abd Pain LUQ Abd Pain LUQ Abd Pain Periumbilical	2700 RxHCC 2705 RxHCC 2702 RxHCC 2701 RxHCC 2707 RxHCC 2706 RxHCC 78906 78907 78904 78902 78905 0K Cancel	
omments Insert special instructions hen click email button.)	C4 C4 CA 125 CA 29-9 CA CEA Calcium, lonized Calcium, lonized Calcium, lonized Calcium, lonized Cell Count, Synovial CK, Isoensymes CK, MB CK, MB	EBV AB Influenza Electrolyte Panel Iron, Serum Endomysial AB Screen Iron, TIBC Erythropoietin Insulin, Fasting ESR Keppra Estradiol KOH Factor V Leiden LDL, Direct Ferritin LH Folic Acid Librium Fructosamine Lipase FSH Lipid Panel	PTH Uri PT/INR Uri PT/INR, Coumadin Clinic Uri PTT Uri Retic Count Uri Retic Count Uri Retic Autor Va RPR w/Reflex Titer VA Rubella, IgG Va Rubella, IgM Va Semen Analysis V Va Sickle Cell Screen VA	ine, Alk ine, Ch ine, So SH alproic , AP Test aricella, aricella, enipur MA, Ra

General Measures

This pop-up reviews seven conditions which are closely linked with CHF which are reviewed on this pop-up. They are:

a. Blood Pressure

The patient's blood pressure will be automatically posted to this pop-up. If it is elevated, the following recommendation will appear, "Better blood pressure control (systolic 110-120 mmHg) is needed. Use hypertension templates and adjust medications."

b. Hyperlipidemia

- Cholesterol/HDL Ratio
- Triglyceride/HDL Ratio

The patient's cholesterol/HDL Ratio will be automatically posted. If it is above 4, the recommendation will state, "**Improved lipid management needed**."

The patient's Triglyceride/HDL Ratio will be automatically posted. If it is above 2, the recommendation wills state, "**Insulin resistance should be evaluated**."

c. Smoking Cessation

• Does the patient smoke

If the patient's history indicates tobacco use, the following recommendation will appear, "Discuss smoking cessation with the patient."

- d. Alcohol use Print patient (info)
- Does the patient drink alcohol? Yes No

If the patient's history indicates alcohol use, the following recommendation will appear, "Continued alcohol use in the face of CHF is harmful."

e. Illicit Drug Use

• Does the patient use illicit drugs? Yes No

If the patient's medical history indicates whether drugs are used or not, it will be automatically posted here. If drugs are used, the following recommendation will appear, "Increasingly illicit drug use is appearing as a cause of CHF, particularly with inhaled cocaine and stimulants."

- f. Diabetes
- Hemoglobin A1C

The patient's Hemoglobin A1C is automatically posted in the box labeled as above. If the value is abnormal the following recommendation appears, "**Optimal control of CHF requires tighter control of hyperglycemia**."

g. Thyroid

- T3
- TSH

The patient's Thyroid values are automatically posted in the boxes labeled as above. If the values are abnormal, the following recommendation appears, "The heart is very dependent on thyroid for proper function. Attention should be given to controlling the patient's thyroid function."

Measures Recommended Action
The heart is very dependent on thyroid for proper function. Attention should be given to controlling the patient's thyroid function.
Cancel

• Fluid Management

This pop-up displays the following options, which can be selected for patient treatment:

Dm Chf Planfluid	×
Fluid Management	
 Restrict daily sodium intake to 2-3 grams per day Daily weight measurement to asses for fluid retention Fluid restriction (to correct clinically important hyponatremia) Strictly avoid high fluid intake (e.g. > 3 liters per day) 	
Information Select the document that you would like to view and click OK.	
C Low Sodium C When To Call Your Doctor C Hyponatremia C Facts for Fluid Retention	
OK Cancel	

• Lung Congestion

The first step in treating DHF patients is to reduce lung congestion. You do that by lowering pulmonary (lung) pressure. This has 3 steps:

- 2. Reduce heart size.
- 3. Make the heart's chambers work together as a team.
- 4. Slowing the heart rate.

Lung Congestion

The first step in treating DHF patients is to reduce lung congestion. You do that by lowering pulmonary (lung) pressure. This has 3 steps:

🗌 1. Reduce heart size.

At first, heart size can be reduced by restricting fluid and sodium intake, by dialysis or filtering the blood, plasmapheresis, and diuretics. Relaxing (dilating) the blood vessels using nitro or morphine is effective but should be started at low doses to avoid low blood pressure. Low blood pressure can be a real problem in DHF patients. Long-term treatment should include small to moderate diuretic doses, mild doses of long-acting nitro, and restricted sodium intake. Aldactone (spironolactone) may be effective long-term because it suppresses the RAS. ACE inhibitors and ARBs reduce fluid retention and oxygen demand.

2. Make the heart's chambers work together as a team.

The second step in lowering pulmonary pressure is to keep the heart's upper chambers (atriums) beating properly. Atrial fibrillation is poorly tolerated in DHF patients because it increases diastolic pressures, causing lung congestion and low blood pressure. In patients with a-fib, restoring normal rhythm should be a priority. Patients who need a pacemaker should have atrial pacing as well as ventricular pacing.

☐ 3. Slowing the heart rate.

The third step in lowering pulmonary pressures is to slow the heart rate. This gives the heart more time to relax so it can fill with blood. Fast heart rate is poorly tolerated in DHF patients because rapid heart rate:

- 1. increases the heart's oxygen demand and reduces blood flow to the heart, causing ischemia even without CAD
- 2. prevents full relaxation of the heart muscle, which raises pressure and reduces the heart's flexibility
- 3. shortens the heart's relaxation period, making it incomplete, which reduces the amount of blood pumped per beat

Select this box and click OK to view and print this information.



• CHF Compliance

The pop-up launched from this button is entitled, "**Factors that may precipitate relapses in patients with pre-existing CHF.**" This is a quick and good review of the potential causes for patient's not responding to treatment for CHF. There is an option to check mark any issue relevant for the care of the patient.

×

Factors that may precipitate relapse	s in patients with pre-existing CHF
 Lack of treatment compliance Myocardial infarction Angina pectoris or painless myocardial ischaemia Alcohol consumption Cardiac arrhythmias Inappropriate medical treatment Infections Anemia 	 Pulmonary embolism Thyroid disease Pregnancy Physical, dietary, fluid, and environmental excesses Emotional stress Systemic hypertension Smoking
Anemia	Cancel

• Medications Precipitating CHF

The pop-up launched from this button is entitled, "Medications Which May

Precipitate/Exacerbate Heart Failure." A quick review of the patient's medications and this list will help in making certain that the treatment of another condition is not fighting against the treatment of CHF.

Negative Inotropes	Medications with Cardiotoxic Properties
Antiarrhythmics	Chemotherapeutic Agents
🔲 disopyramide (Norpace)	🗖 doxorubicin
🔲 flecainide (Tambocor)	🗖 daunorubicin
Beta Blockers	Cyclophosphamide
🔲 pindolol (Blocarden, Corgard, Sectral, Visken)	Cocaine
acebutolol	Amphetamines
Calcium Channel Agonists	Agents Causing Sodium and Water Retention
🗖 verapamil	Estrogen
🔲 diltiazem	
nifedipine (Adalat CC)	☐ qlucocorticoids
felodipine (Plendil)	□ salicylates (high-dose)
Expansion of Blood Volume	Drugs with high sodium content (carbenicillin, ticarcil
hydralazine	
minoxidil (Loniten)	

Additional Management

This is a list of important, but ancillary issues for the effective and excellent treatment of CHF. There is an option for check marking the ones related to this patient.

×

Dm Chf Planmng	×
Additional Management	
 ✓ Flu vaccination every fall Last Flu Shot D5/30/2007 Pneumovax every 5 years 	
OK	

• Follow Up Instructions

This is a list of instructions which are automatically checked and placed on the patient's CHF follow-up note.

Dm Chf Planfollow	×
Follow Up Instructions	
 Blood Pressure Diary SETMA CHF educational booklet given to patient or family Compliance encouraged Adherence to non-pharmacological measures Adverse effects of therapy discussed Blood in stool Blood in urine Chest pain Decreased appetite Easy bruising Fatigue Light headiness Muscle cramps Shortness of breath 	
OK	

• CHF Compliance E-mail

This is a link which launches an **electronic tickler file**. When activated, the following steps are taken:

- A pop-up appears which asks "Attach Patient's Document." The option entitled "This template" should be selected.
- Then click OK.
- An e-mail appears which has the following text automatically placed:
- Please call Test IBM Serv AAA at 4098354550 to remind them to: (1) weigh daily and call if more than 3 pounds is gained, (2) take all medications as prescribed, (3) avoid salt in diet, (4) keep appointments, (5) follow their CHF exercise prescription, (6) review their CHF follow-up document, and (7) review their CHF patient education booklet. This patient should be called at least once a week and the telephone call documented in the EMR.
- Send the e-mail to your nurse and/or your unit clerk. You can also copy it to yourself.
- Before clicking send, go to "Options."
- On the Options pop-up select, "Do not send delivery before," and select a date one week, two weeks or whatever appropriate interval the patient's condition warrants the telephone follow-up.
- Then click send.

This electronic tickler file will sit on the server until the appointed date, at which time it will appear on the addressee's desktop. The follow-up telephone call can be made; the information can be given; the contract can be documented; and if appropriate, another electronic tickler file for one week, etc. can be created to remind you to follow-up with this patient.

	CHF Treatment Plan	
Hydration Lipid:	s Diabetes Metabolic Syndrome Weight Management Hypertension	
Seven Steps to Success		Return
Focus of Treatment	CHF Status C Improved C No Change C Worse	Document
Evaluation Orde	ring Provider Holly James	Follow-Up Doc
General Measures	ratory Immunizations	
Fluid Management	BMP Potassium Flu Shot Pneumovax	
VVeight Loss Info	oroBNP PAttach X	
Exercise	CMP T Attach Patient's Document	
Smoking Cessation		
Lung Congestion	Lipid Panel w/LDL V	
CHF Compliance Rad	tiology	
Meds Precipitating CHF	EKG Che O This Template	
Additional Management		
Follow Up Instructions		
CHF Compliance Email		
Referrals (double-click to add)	Medication:	Information
Priority Referring First Referring Last	Referral Brand Name	Echocardiography
	HYDROXY	Teke Cere Self
	apidra 100 unit p	Siven
	apidra 100 unit p	Lifestyle Changes

At the top of the middle section of the CHF Plan Template, there is a place to document the CHF Status of the patient. The options are:

Hydration	1	Lipid	CHF 7		an Veight Manager	nent <u>Hyper</u>	tension		
Seven Steps to Success				C	No. Ohio and	Charles	1	Return	
Focus of Treatment			CHF Status	s O improved O	No Change	• vvorse		Document	
Evaluation		Orde	ering Provid	er Holly	James			Follow-Up Do	oc
General Measures		Labo	ratory		Immur	izations			
Fluid Management			BMP	🔲 Potassium	🔲 Flu	Shot	Pneumovax		
VVeight Loss	Info		proBNP						
Exercise		- 23	CMP	I Thyroid Pro	file Dx1				
Smoking Cessation		E i	Digoxin		Dx 2				
Lung Congestion		Ē	Lipid Panel w	ALDL 🔲 Venipunct	ure Dx 3				
CHF Compliance		Rac	diology			Culumit Cl	nave Desting		
Meds Precipitating CHF	Info	Г	EKG	📃 Chest PA/Lat		Subhit Ci	large Posiling		
Additional Management				🔲 Chest 1 View					
(Follow Up Instructions)									
CHF Compliance Email				Medication	n Info				
Referrals (double-clic	k to add)			Medications (double	click to add)	1	ollow Up	In	formation
Priority Referring First	Referring	Last	Referral	Brand Name	Dose	_		Echo	cardiograph
	-			HYDROXYZINE HCL	25MG			Rel	apse Control
N 199	10			apidra	100 unit p		ducation Booklet Gi	Ta	ke Care Self
				apidra	100 unit p			Lifes	style Change:
							1		

Beneath the Status in the middle section of the CHF Plan Template is a list of Laboratory studies, procedures and Immunizations which can be ordered and charge posted from the CHF Plan Template.

		CH	F Treatment P	lan		-
Hydration		Lipids Diab	etes Metabolic Syndrome	Weight Management	Hypertension	
Seven Steps to Success						Return
Focus of Treatment		CHF S	Status 🔿 Improved 🤇	No Change 🛛 🔿 Wo	orse	Document
Evaluation		Ordering Pr	ovider Holly	James		Follow-Up Doc
General Measures		Laboratory		Immunizatio	08	
Fluid Management		BMP	🔲 Potassium	Flu Shot	Pneumovax	
Weight Loss	Info	🔲 proBNP	PT/INR			
Exercise			Thyroid Pro	ofile		
Smoking Cessation			I Troponin	Dx 2		
Lung Congestion		Lipid Par	nel w/LDL 🔽 Venipund	ture Dx 3		
CHF Compliance		Radiology			all Change Desting	
Meds Precipitating CHF	Info	EKG	🔲 Chest PA/Lat	Subi	mit Charge Posting	
Additional Management			🔲 Chest 1 View	,		
(Follow Up Instructions)						
CHF Compliance Email			Medicatio	on Info		
Referrals (double-click	to add)		Medications (double	e-click to add)	Follow Up	Information
Priority Referring First	Referring	Last Referra	al Brand Name	Dose	▲	Echocardiography
			HYDROXYZINE HCL	25MG		Relapse Control
			apidra	100 unit p	Education Booklet G	iven
			apidra	100 unit p		Lifestyle Changes
				1		
						•

Once the ICD-9 Code has been added and once the lab studies or procedures have been selected, click on the "Submit Charge Posting" button.

The right side of the CHF Plan has three buttons:

	CHF	Treatment Pla	an		<u> </u>
Hydration	Lipids Diabetes	Metabolic Syndrome W	eight Management Hy	pertension	
Seven Stens to Success					Return
Focus of Treatment	CHF State	us 🔿 Improved 🔿 I	No Change 🛛 🔿 Wor:	se 🗖	Document
Evaluation	Ordering Provi	der Halls	lane and		
General Measures	Videning From	Holly	James	Fo	llow-Up Doc
Fluid Management		C Determine	Immunization:	s Decumentary	
Weight Loss			j Flu Shot	jPrieumovax	
Exercise	CMP	Thyroid Profi	le		
Smoking Cessation		🔲 Troponin	Dx 1		
Lung Congestion	Digoxin	Urinalysis	DX2 J		
CHF Compliance	Padiology		ie Dx3 j		
Meds Precipitating CHF		Chest PA/Lat	Submi	t Charge Posting	
Additional Management		Chest 1 View			
[Follow Up Instructions]					
CHF Compliance Email		Medication	Info		
		Medicatione (double)	click to add)	Follow Up	Information
Referrals (double-click to add)		INCULUIUNS INUUNC-			
Referrals (double-click to add)	a Loct Referrel	Brand Name	Dooo		Echocardiography
Referrals (double-click to add) Priority Referring First Referring	g Last Referral	Brand Name HYDROXYZINE HCL	Dose A		Echocardiography Relapse Control
Referrals (double-click to add) Priority Referring First Referring	g Last Referral	Brand Name HYDROXYZINE HCL apidra	Dose 25MG 100 unit p		Echocardiography Relapse Control Take Care Self
Referrals (double-click to add) Priority Referring First Referring	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose A 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes
Referrals (double-click to add) Priority Referring First Referring	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes
Referrals (double-click to add) Priority Referring First Referring	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes
Referrals (double-click to add) Priority Referring First Referring Image: Click to add Image: Click to add Image: Click to add	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes
Referrals (double-click to add) Priority Referring First Referring Image: state s	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes
Referrals (double-click to add) Priority Referring First Referring Image: state s	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes
Referrals (double-click to add) Priority Referring First Referring Image: state s	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes
Referrals (double-click to add) Priority Referring First Referring Image: state s	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes
Referrals (double-click to add) Priority Referring First Referring Image: state s	g Last Referral	Brand Name HYDROXYZINE HCL apidra apidra	Dose 25MG 100 unit p 100 unit p	Education Booklet Given	Echocardiography Relapse Control Take Care Self Lifestyle Changes

Across the bottom of the CHF Plan Template there are the following:

- <u>Referral</u> Link
- <u>Medications Module</u> Link
- Follow-up Visit documentation
- Education Booklet Given Documentation
- **Information** these are printable documents:
 - 1. Echocardiography
 - 2. Relapse Control
 - 3. Take Care Self
 - 4. Lifestyle Changes

Medication Information

Above the medication Module Link, there is a button entitled "**Medication Info.**" Depressing this button launches a pop-up entitled CHF Medications.

Hydration Lipids Diabetes Metabolic Syndrome Weight Management Hypertension Seven Steps to Success CHF Status Focus of Treatment CHF Status Evaluation Ordering Provider Holly General Measures Info Fluid Management BMP Potassium Flu Shot Provider Holly James Fluid Management BMP Ordering Provider Holly James Fluid Management BMP Ordering Provider Holly James Fluid Management BMP Ordering Provider Holly Potassium Fluid Management BMP Ordering Provider Holly Potassium Fluid Management BMP Ordering Provider Holly Potassium Info proBNP Ordering Provider Holly Potassium BMP Potassium Potassium Flu Shot Preumovax Preumovax Weight Loss Info Ordering Provider Holly Potassium Info proBNP Ordering Propinin D1 Ordering Propinin D1 Digoxin Urinalysis Digoxin Urinalysis Upid Panel w/LDL Venipuncture Venipuncture D3 CHF Compliance Radiology Meds Precipitating CHF Info Info EKG Chest I View
Seven Steps to Success Refurn Focus of Treatment CHF Status Evaluation Ordering Provider General Measures Laboratory Fluid Management BMP Potassium Flu Shot Provider Potassium Fluid Management BMP Provider Potassium Fluid Management BMP Provider Potassium Fluid Management BMP Provider Potassium Fluid Management Document BMP Potassium Fluid Management BMP Document BMP Provider Provider BMP Potassium Fluid Management BMP CHF Compliance CHF Radiology Submit Charge Posting Meds Precipitating CHF Info Info EKG Chest PA/Lat Chest 1 View
Focus of Treatment Ordering Provider Holly James Document Evaluation Ordering Provider Holly James Follow-Up Doc General Measures Laboratory Immunizations Follow-Up Doc Fluid Management BMP Potassium Flu Shot Pneumovax Weight Loss Info proBNP PT/NR Exercise CMP Thyroid Profile Document Smoking Cessation Digoxin Urinalysis Dx 2 Lung Congestion Lipid Panel w/LDL Venipuncture Dx 3 CHF Compliance Radiology Submit Charge Posting Meds Precipitating CHF Info EKG Chest PA/Lat Additional Management Chest 1 View Submit Charge Posting
Evaluation Ordering Provider Holly James General Measures Laboratory Immunizations Fluid Management BMP Potassium Flu Shot Pneumovax Weight Loss Info proBNP PT/INR Exercise CMP Thyroid Profile Smoking Cessation Digoxin Urinalysis Dx 2 Lung Congestion Lipid Panel w/LDL Venipuncture Dx 3 CHF Compliance Radiology Submit Charge Posting Meds Precipitating CHF Info EKG Chest PA/Lat Additional Management Chest 1 View View
General Measures Laboratory Immunizations Fluid Management BMP Potassium Flu Shot Pneumovax Weight Loss Info proBNP PT/INR Exercise CMP Thyroid Profile Smoking Cessation Digoxin Urinalysis Dx 1 Lung Congestion Lipid Panel w/LDL Venipuncture Dx 3 CHF Compliance Radiology Submit Charge Posting Meds Precipitating CHF Info EKG Chest PA/Lat Additional Management Chest 1 View Lipid View
Pidd Wardgenenit BMP Potassium Flu Shot Pneumovax Weight Loss Info proBNP PT/INR Exercise CMP Thyroid Profile Smoking Cessation Digoxin Urinalysis Dx 1 Lung Congestion Lipid Panel w/LDL Venipuncture Dx 3 CHF Compliance Radiology Submit Charge Posting Meds Precipitating CHF Info EKG Chest PA/Lat Additional Management Chest 1 View Lipid View
Exercise CMP Thyroid Profile Smoking Cessation CPK Troponin Dx1 Lung Congestion Digoxin Urinalysis Dx 2 Lung Congestion Lipid Panel w/LDL Venipuncture Dx 3 CHF Compliance Radiology Submit Charge Posting Meds Precipitating CHF Info EKG Chest PA/Lat Additional Management Chest 1 View Venipuncture Venipuncture
CPK Troponin Dx 1 Smoking Cessation Digoxin Urinalysis Dx 2 Lung Congestion Lipid Panel w/LDL Venipuncture Dx 3 CHF Compliance Radiology Dx 3 Submit Charge Posting Meds Precipitating CHF Info EKG Chest PA/Lat Submit Charge Posting Additional Management Chest 1 View Venipuncture Dx 3 Submit Charge Posting
Lung Congestion Digoxin Urinalysis Dx 2 Lung Congestion Lipid Panel w/LDL Venipuncture Dx 3 CHF Compliance Radiology Dx 3 Meds Precipitating CHF Info EKG Chest PA/Lat Additional Management Chest 1 View Submit Charge Posting
CHF Compliance Radiology Meds Precipitating CHF Info Additional Management Chest PA/Lat Submit Charge Posting
Meds Precipitating CHF Info EKG Chest PA/Lat Additional Management Chest 1 View
Additional Management Chest 1 View
(Follow Up Instructions)
CHF Compliance Email Medication Info
Referrals (double-click to add) Medications (double-click to add) Follow Up Information
Priority Referring First Referring Last Referral Brand Name Dose
HYDROXYZINE HCL 25MG Take Care Self
apidra 100 unit p Education Booklet Given

By selecting a category of medications and then selecting a drug in that category, it is possible to review on line the following:

- Adult Dose
- Pediatric Dose
- Pregnancy Warning
- General Information
- Interactions
- Precautions
- Contraindications

for each of the drugs used in the treatment of congestive heart failure.

Dm Chf Medics					×
		CHF Med	dications		
1. Select a drug category.					
O ACE Inhibitors O A	ngiotensin Receptor Bloc	kers 🔿 Beta-A	drenergic Blockers 📀	Calcium Channel Blockers 🔘 D)iuretics
C Human B-Type Natriu	iretic Peptides 🛛 🔿 Inc	tropic Agents	C Phosphodiesteras	se Enzyme Inhibitors 🛛 🔿 Vas	odilators
2. Select a drug.		3. View the a	vailable information.	y Nanazo no na visionen y	
		(If necessar additional inf	y, click in a box and us formation in the boxes b	e the arrow keys to scroll throug below.)	h
		General Infor	mation		
Adult Dose	Interactions	I	Precautions	Contraindication	s
Pediatric Dose					
Pregnancy					
		ок	Cancel		

Dm Chf Medics				×	
	С	HF Me	dications		
1. Select a drug category. ACE Inhibitors C Ar C Human B-Type Natriu	ngiotensin Receptor Blocke retic Peptides 🛛 C Inotro	ers O Beta-, opic Agents	Adrenergic Blockers 🔘 Calcium Chai	nnel Blockers 🔿 Diuretics nibitors 🔿 Vasodilators	
2. Select a drug.	:	3. View the	available information.		
C Captopril (Capoten) C Enalapril (Vasotec)		(If necessa additional ir	rry, click in a box and use the arrow k nformation in the boxes below.)	eys to scroll through	
Quinapril (Accupril) General Information					
C Lisinopril (Prinivil, Zestril) Ramiprii (Altace) Fosinopril (Monopril) Prevent conversion of Ang I to Ang II (a potent vasoconstrictor), resulting in increased levels of plasma renin and a reduction in aldosterone secretion.					
Adult Dose	Interactions		Precautions	Contraindications	
Adult Dose 10 mg/d P0 initially; may increase to 20-40 mg/d qd or divided bid Pediatric Dose	Interactions NSAIDs may reduce hypot effects of ACE inhibitors; inhibitors may increase dig and allopurinol levels; rifam decreases ACE inhibitor lev probenecid may increase A levels; hypotensive effect	tensive ACE joxin, lithium, npin vels; ACE inhibitor ts of ACE	Precautions Category D in second and third trimester of pregnancy; caution in renal impairment, valvular stenosis, or severe CHF	Contraindications Documented hypersensitivity; renal impairment, angioedema	
Aduit Dose 10 mg/d PO initially; may increase to 20-40 mg/d qd or divided bid Pediatric Dose Not established	Interactions NSAIDs may reduce hypot effects of ACE inhibitors; inhibitors may increase dig and allopurinol levels; nfam decreases ACE inhibitor lev probenecid may increase A levels; hypotensive effect inhibitors may be enhanced concurrently administered of	tensive ACE poxin, lithium, npin vels; ACE inhibitor Is of ACE d when with diuretics	Precautions Category D in second and third trimester of pregnancy; caution in renal impaiment, valvular stenosis, or severe CHF	Contraindications Documented hypersensitivity; renal impairment, angioedema	
Adult Dose 10 mg/d PO initially; may increase to 20-40 mg/d qd or divided bid Pediatric Dose Not established Pregnancy	Interactions NSAIDs may reduce hypor effects of ACE inhibitors; inhibitors may increase dig and allopurinol levels; rifan decreases ACE inhibitor lev probenecid may increase A levels; hypotensive effect inhibitors may be enhanced concurrently administered to	tensive ACE joxin, lithium, npin vels; ACE inhibitor Is of ACE d when with diuretios	Precautions Category D in second and third trimester of pregnancy; caution in renal impairment, valvular stenosis, or severe CHF	Contraindications Documented hypersensitivity; renal impaiment, angioedema	
Adult Dose 10 mg/d PO initially; may increase to 20-40 mg/d qd or divided bid Pediatric Dose Not established Pregnancy D - Unsafe in pregnancy	Interactions NSAIDs may reduce hypor effects of ACE inhibitors; inhibitors may increase dig and allopurinol levels; iffan decreases ACE inhibitor lev probenecid may increase 4 levels; hypotensive effect inhibitors may be enhanced concurrently administered to	tensive ACE Joxin, lithium, npin vels; ACE inhibitor ts of ACE d when with diuretics	Precautions Category D in second and third trimester of pregnancy; caution in renal impairment, valvular stenosis, or severe CHF	Contraindications Documented hypersensitivity; renal impairment, angioedema	

Dm Chf Medics			×
	CHF M	ledications	
1. Select a drug category.			
🔘 ACE Inhibitors 🔘 Ang	giotensin Receptor Blockers 🔘 Be	a-Adrenergic Blockers 🔘 Calcium Cha	nnel Blockers 🔘 Diuretics
O Human B-Type Natriure	etic Peptides 🛛 🔘 Inotropic Agent	s • Phosphodiesterase Enzyme Inf	nibitors 🔘 Vasodilators
2. Select a drug.	3. View th	e available information.	
Milrinone (Primacor)	(If nece: addition	ssary, click in a box and use the arrow k al information in the boxes below.)	eys to scroll through
	General I	nformation	
	Positive ind increased o demonstrat improveme consumptio	stropic agent and vasodilator. Results in reduc andiac output. Several studies comparing milri ed that milrinone showed greater improvement nts in cardiac output, without significant increa n.	ed afterload, reduced preload, and none to dobutamine have is in preload and afterload and ises in myocardial oxygen
Adult Dose	Interactions	Precautions	Contraindications
50 mog/kg IV loading dose over 10 min, followed by continuous infusion at 0.25-1.0 mog/kg/min; titrate to maintain adequate systolic blood pressure and cardiac output Pediatric Dose Not established Pregnancy C - Safety for use during pregnancy has not been established.	Precipitates in presence of furosemide	Monitor fluids, electrolyte changes, and renal function during therapy; excessive diuresis may increase potassium loss and predispose digitalized patients to arrhythmias (correct hypokalemia with potassium supplementation prior to treatment); slow rates or stop infusion in patients showing excessive decreases in blood pressure; previous vigorous diuretio therapy has caused significant decreases in cardiac filling pressure; administer cautiously and monitor bloodpressure, heart rate, and clinical symptomatology	Documented hypersensitivity; obstructive hypertrophic cardiomyopathy
	OK	Cancel	

CHF Questionnaire Template

This is a 21-question tool which scores the functional capacity of a patient with CHF. The lower the score the better the patient is doing. When the questionnaire is scored, it is possible to review all of the scores for this patient in a longitudinal fashion which will give some indication of the progress the patient is or is not making.

Living With Heart Failure Que	stic	nna	aire				
If you are sure an item does not apply to you or is not related to your	heart 1	failure,	then s	elect "	0".		
If an item does apply to you then select the number rating how much it preve	ented y No	ou from Verv	n living Little	as yo	Verv	nted. / Much	Return
Print Form	0	1	2	3	4	5	
1. Causing swelling in your ankles, legs, etc.?	0	0	0	0	0	C	
2. Making your working around the house or vard more difficult?	0	0	0	0	0	C	
3. Making your relating to or doing things with your friends or family difficult?	C	C	0	0	0	0	
4 Making you sit or lie down to rest during the day?	0	C	0	0	0	0	
5. Making you tired, fatigued or low on energy?	0	C	0	0	0	C	
6 Making your working to earn a living difficult?	0	C	C	0	C	C	
7 Making your walking about or climbing un stairs difficult?	C	C	0	C	0	C	
8 Making you short of breath?	0	0	0	0	0	ò	
9 Making your steening well at night difficult?	0	C	0	0	0	C	
10. Making your stopping worldk right announces	0	C	0	0	0	õ	
11. Making you can use of the roous you find?	C	C	0	0	0	ò	
12 Making your sexual activities difficult?	0	C.	C	0	0	ò	
13. Making your recreational nasttimes shorts or hobbies difficult?	0	0	0	0	0	0	
14. Making it difficult for you to concentrate and remember things?	0	0	0	0	0	C	
15. Giving you side effects from medications?	0	C	C	0	C	C	
16 Making you worry?	C	C	C	0	0	C	
17 Making you feel depressed?	0	0	C	0	0	C	
18 Costing you money for medical care?	0	C	0	0	C	C	
19. Making you feel a loss of self-control of your life?	0	0	0	0	0	C .	
20. Making you stay in the hospital?	0	0	0	0	0	0	
21. Making you feel you are a burden to your family or friends?	0	0	0	C	0	0	
Previous Questionnaire Results							
Encounter Date: Time Total Points							
				The	lowe	er your score	
				une	Dette	a on you are.	
						1	
							Þ

Flow sheet Template

The name of this template is, "**Prospective Data Collection Flow sheet**." The data which is automatically collected on each patient when the CHF templates are given is in accordance with the Physician Consortium for Performance Improve Data Set on CHF. The elements of this data set are:

- Assessment of clinical Symptoms of Volume Overload (Excess)
- Level of Activity
- Assessment of clinical Sign of Volume overload (excess)
- Patient Education
- Beta-Blocker Therapy
- Ace Inhibitor Therapy
- Warfarin Therapy

Chronic Hx paroxysmal Atrial Fib

Once the evaluation of a patient with CHF is complete, the provider can review this template to see if all of the elements of a quality evaluation of a patient with CHF have been met.

CH	IF Manageme	Patient Robert	t Test Jr		Home	^	
Goals of Therapy	Differentiating	Causes	Sex	M Age 39		Nursing	
Diag	nosing Classific	cation				Histories	
Vital Signs		Most Recent Labs	Check for New	/Labs		Health	
Height	72.00 inches	Sodium	11	Cholesterol 150	06/06/2007	Questionnaires	
Weight	00 pounds	Potassium		Triglycerides 175	06/06/2007	System Review	
Body Fat	22 %		11		11	Physical Exam	
BMR	cal/day	Glucose	11	Chol/HDL		Radiology	
rVaist	.00 inches	BUN	11	Trig/HDL		Procedures	
Hips Risk Ratio	00 inches	Creatinine		UA Protein		Treatment Guide	
Blood Pressure			11	T4	11	Treatment Plan	
/	mmHg	СРК	11	77	11	CHF Questionnaire	
Pulse Last Echo	11	Digoxin		T-Uptake		Flowsheet	
Ejection Fraction	.00 Help	INR	11	proBNP	11		
Ventricular Dys	Systolic Help	Fibrinogen	11	Sed Rate	11		
CHF Class	Class II Help	PAI-1	11	D-Dimer	11		
Framingham 10-Yr	<u>Risk</u> %				1	Patient Info	
Mortality Risk		N	Medical History	Labs Over Time		Provider Info	
<u>Global Cardio Risk</u>	1.4					CHF Primer	
						Treatment	
						Diagnosing Adults	
							-
•							

Prospective Data Collection Flowsheet							
	No Yes						
Assessment of Clinical Symptoms of Volume Overload (Excess)	Image: Dyspnea Return Image: Fatique Image: Dyspnea Image: Dyspnea Questionnaire Score Image: Standardized scale or assessment tool used Questionnaire Score						
Level of Activity	Standardized scale or assessment tool used						
Assessment of Clinical Signs of Volume Overload (Excess)	Peripheral Edema Rales Icure Enlarged (Hepatomegaly) Ascites Jugular Venous Pulse - Normal Jugular Venous Pulse - Distended						
Patient Education	Patient Education Given						
Beta-Blocker Therapy	Not Indicated Prescribed Not Prescribed (Medical Reasons) Not Prescribed (Patient Reasons) Patient refuses a B-blocker						
Ace Inhibitor Therapy	Not Indicated Prescribed Not Prescribed (Patient Reasons) Patient Receiving Angiotensin Receptor Blocker Patient refuses an ACE Patient refuses an ARB						
Warfarin Therapy Chronic Hx Paroxysmal Atrial Fib	✓ Not Indicated Prescribed Not Prescribed (Medical Reasons) ✓ Not Prescribed (Patient Reasons)	-					

Rails – automatic documentation from respiratory physical examination template. The documentation of the presences or the absence of rails is one of the quality indicators established by the Physicians Consortium for performance improvements.

The final step is to give the patient a copy of the CHF follow-up note.